Commentary Open Access
Volume 3 | Issue 5 | DOI: https://doi.org/10.33696/immunology.3.112]
COVID-19 Clinical Outcomes and Vaccine Efficacy among Patients with Hematologic Malignancies
Sarah Gillaspie1,*, Marc S Hoffmann2,*
- 1niversity of Kansas School of Medicine, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
- 2Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, 2650 Shawnee Mission Pkwy, Kansas City, KS 66205, USA
Corresponding Author
Sarah Gillaspie, sgillaspie@kumc.edu;
Marc S Hoffmann, mhoffmann@kumc.edu
Received Date: June 18, 2021
Accepted Date: September 22, 2021
Gillaspie S, Hoffmann S. COVID-19 Clinical Outcomes and Vaccine Efficacy among Patients with Hematologic Malignancies. J Cell Immunol. 2021; 3(5): 317-320.
Copyright: © 2021 Gillaspie S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
COVID-19, Hematologic malignancy, Chemotherapy, Lymphopenia, COVID-19 vaccine, Vaccine efficacy
Recommended Articles
How Well Do Hemodialysis Patients Respond to the BNT162b2 mRNA COVID-19 Vaccine?
In January 2020, the World Health Organization (WHO) classified COVID-19 to be a Public Health Emergency of International Concern and declared it a pandemic on March 11, 2020 [1]. Over one hundred and eighty-five million people have been infected by SARS-CoV-2 and roughly four million have died worldwide so far
Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy for Breast Cancer
Breast cancer is the second most common cancer worldwide, affecting nearly one in eight women. Accurate cancer staging is essential for determining the patient’s prognosis and for choosing the appropriate treatment. The staging system most often used is the American Joint Committee on Cancer (AJCC) TNM system, where T refers to the size of the tumor, N refers to spread of the primary cancer to nearby lymph nodes, and M refers to the spread of metastasis to distant sites in the body.
Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery in Stage 1B2 Cervical Cancer
In 2020 we published a series of 18 patients who underwent neoadjuvant chemotherapy (NACT) and vaginal radical trachelectomy (VRT) as a fertility sparing alternative in stage 1B2 cervical cancer.
Relative COVID-19 Vaccine Booster Effectiveness and ClinicalEpidemiological Characteristics Before and After 29 Days of Shot
Background: When the highest vaccine COVID-19 booster effectiveness (VBE) is obtained is not clearly known. Objective: To compare the cases of COVID-19 in booster vaccinated people with a time of <29 days vs. ≥ 29 days from booster to infection diagnosis and assess their relative VBE. Methodology: An observational, longitudinal and prospective case series study of adult patients with COVID-19 breakthrough infections in booster vaccinated people, in general medicine and for the period December 2021 to February 2022, during the omicron variant contagion wave.
Late ECG Changes after Cisplatin-Based Chemotherapy in Testicular Cancer Survivors
Introducing cisplatin-based therapy into testicular cancer treatment represents a substantial progress in therapy leading to a longer survival of patients and less adverse effects; currently it represents the standard therapy.